Hyfinity Investments

Hyfinity Investments is a venture capital firm based in Beijing, China, specializing in healthcare and biotechnology sectors. The firm is led by senior partners from top-tier investment institutions in China, with extensive experience in healthcare investment, local operations, and overseas licensing. Their mission is to advance global innovations by partnering with companies addressing high unmet needs and leveraging China's rich clinical resources.

The firm's investment strategy targets early to late-stage ventures, including Series A, Series B, growth, late-stage, and pre-IPO companies. They focus on sectors such as biotechnology, healthcare, medical devices, pharmaceuticals, and biopharmaceuticals. Hyfinity Investments has a history of co-leading significant financing rounds, such as the US$57 million Series C financing for Oculis S.A., a late-stage biopharmaceutical company specializing in ophthalmic treatments.

Hyfinity Investments has invested in various companies, including Oculis Holding AG, Beijing Surgerii Robotics Co., Ltd., and Novozymes (Suzhou) Medical Technology Co., Ltd. Their portfolio also includes Hexaell Biotech, a Shanghai-based company specializing in bio-artificial liver organs, which secured a Series A round of 50 million RMB (approximately $7.3 million) from Hyfinity Investments in December 2018. This investment supports Hexaell's clinical and CFDA registration of the hiHep cell engineering system and accelerates research and development in liver diseases and cell engineering pipelines.

Hyfinity Investments is committed to fostering industry leaders by converging global resources, aiming to minimize risks and maximize returns for their portfolio companies. Their approach includes providing post-investment value-added services, from clinical resources to the industrial chain, to accelerate corporate growth and reduce risks.